Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.

Sagar Lonial, Monique C. Minnema, Thierry Façon et al.|Journal of Clinical Oncology|2022

Cited by 25